{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T05:11:26Z","timestamp":1695618686131},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,1,29]],"date-time":"2016-01-29T00:00:00Z","timestamp":1454025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In the literature, there are minimal data for the treatment of grade 2 or 3 morbilliform\/atypical target lesion rashes secondary to sorafenib or vemurafenib given for patients with advanced stage cancer. This poses a dilemma for clinicians, particularly in patients with advanced neoplastic disease for whom other optional treatments are limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The cohort included data on all patients attending the dermato\u2010oncological clinic at a tertiary medical center that presented in 2011\u20132014 with a widespread rash following treatment with sorafenib or vemurafenib. All patients were prospectively followed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eight patients met the study criteria. Five, under sorafenib, aged 50\u201365 years, presented with an extensive grade 2 (involving 20\u201330% of the body surface area, two patients) or grade 3 (three patients) morbilliform rash, 5\u201310 days after onset of the drug. Two had atypical target lesions. The dosage was temporarily reduced in only two patients, and oral steroids were added in four. Under vemurafenib, three patients presented with an extensive grade 3 morbilliform rash 5\u201310 days after onset of treatment. Two had atypical target lesions. The dose was temporarily reduced in one, and another patient stopped the drug at her own initiative; both also received steroids. The rash subsided after 2\u20133 weeks in all eight patients, allowing continuation of the treatment at the regular dose.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our cohort suggests that not all cases of widespread morbilliform rash or atypical erythema multiforme, which occur under treatment with sorafenib or vemurafenib, given for advanced cancer, require discontinuation of therapy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ijd.13153","type":"journal-article","created":{"date-parts":[[2016,1,30]],"date-time":"2016-01-30T01:24:47Z","timestamp":1454117087000},"page":"473-478","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato\u2010oncology clinic"],"prefix":"10.1111","volume":"55","author":[{"given":"Ayelet","family":"Ollech","sequence":"first","affiliation":[{"name":"Department of Dermatology Rabin Medical Center Petach Tikva Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salomon M.","family":"Stemmer","sequence":"additional","affiliation":[{"name":"Institute of Oncology Davidoff Center Rabin Medical Center Petach Tikva Israel"},{"name":"Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Merims","sequence":"additional","affiliation":[{"name":"Center for Melanoma and Cancer Immunotherapy Sharett Institute of Oncology Hadassah Hebrew University Medical Center Jerusalem Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Lotem","sequence":"additional","affiliation":[{"name":"Center for Melanoma and Cancer Immunotherapy Sharett Institute of Oncology Hadassah Hebrew University Medical Center Jerusalem Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aron","family":"Popovtzer","sequence":"additional","affiliation":[{"name":"Institute of Oncology Davidoff Center Rabin Medical Center Petach Tikva Israel"},{"name":"Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Hendler","sequence":"additional","affiliation":[{"name":"Institute of Oncology Davidoff Center Rabin Medical Center Petach Tikva Israel"},{"name":"Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmilia","family":"Hodak","sequence":"additional","affiliation":[{"name":"Department of Dermatology Rabin Medical Center Petach Tikva Israel"},{"name":"Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Didkovsky","sequence":"additional","affiliation":[{"name":"Department of Pathology Rabin Medical Center Petach Tikva Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Amitay\u2010Laish","sequence":"additional","affiliation":[{"name":"Department of Dermatology Rabin Medical Center Petach Tikva Israel"},{"name":"Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,1,29]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1443"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060655"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60421-9"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.06.034"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2011.04060.x"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0333"},{"key":"e_1_2_5_10_1","unstructured":"National Cancer Institute.Common Terminology Criteria for Adverse Events v.4.0 (CTCAE). Available at:http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm(accessed on 4 November 2014)"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hys103"},{"key":"e_1_2_5_12_1","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1684\/ejd.2011.1535","article-title":"Sorafenib\u2010induced erythema multiforme: three cases","volume":"21","author":"Namba M","year":"2011","journal-title":"Eur J Dermatol"},{"key":"e_1_2_5_13_1","first-page":"1462","article-title":"Erythema multiforme\u2010like drug reaction to sorafenib","volume":"10","author":"Lewin J","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq299"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03320.x"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/15569520902915469"},{"key":"e_1_2_5_17_1","first-page":"891","article-title":"Cutaneous drug eruptions induced by sorafenib: a case series","volume":"7","author":"Maddox JS","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.10.981"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2011.23.S3.S404"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e3283573437"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000110"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2324-5"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijd.13153","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.13153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T10:14:13Z","timestamp":1695550453000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.13153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,29]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1111\/ijd.13153"],"URL":"https:\/\/doi.org\/10.1111\/ijd.13153","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,29]]},"assertion":[{"value":"2015-01-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-07-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-01-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}